| Institution: | 1. Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York;2. Department of Biostatistics, The Rockefeller University, New York, New York;3. Albert Einstein College of Medicine, Bronx, New York;4. Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, Weill Cornell University, New York, New York;1. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania;2. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania;1. Harvard Medical School, Boston, Massachusetts;2. AbbVie Inc, North Chicago, Illinois;3. Adelphi Values, Boston, Massachusetts;4. Clinical Outcomes Solutions, Tucson, Arizona;5. Fort HealthCare, Fort Atkinson, Wisconsin;1. Department of Dermatology at Roskilde Hospital, Roskilde, Denmark;2. Department of Dermatology at Deventer Hospital, Deventer, The Netherlands;3. Department of Dermatology at Erasmus University Medical Center, Rotterdam, The Netherlands;4. Section of Dermatology and Venereology, Department of Medicine, Huddinge at Karolinska Institutet, Stockholm, Sweden;5. Department of Dermatology, Stockholm South General Hospital, Stockholm, Sweden;1. Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York;2. Weill Cornell/Rockefeller/Sloan Kettering Tri-institutional MD-PhD Program, Weill Cornell Medicine, New York, New York;3. Albert Einstein College of Medicine, Bronx, New York;4. Icahn School of Medicine at Mount Sinai, New York, New York |
